Azra Hussaini

464 total citations
14 papers, 258 citations indexed

About

Azra Hussaini is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Azra Hussaini has authored 14 papers receiving a total of 258 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 3 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in Azra Hussaini's work include Prostate Cancer Treatment and Research (2 papers), HIV Research and Treatment (1 paper) and Radiopharmaceutical Chemistry and Applications (1 paper). Azra Hussaini is often cited by papers focused on Prostate Cancer Treatment and Research (2 papers), HIV Research and Treatment (1 paper) and Radiopharmaceutical Chemistry and Applications (1 paper). Azra Hussaini collaborates with scholars based in United States, United Kingdom and Switzerland. Azra Hussaini's co-authors include Paul R. Nemeth, Bill Bosch, Ronald Goldwater, Khadeeja Mohamed, Justin A. Green, Joan R. Butterton, Stephan Duparc, Marian Iwamoto, Arne van Schanke and Fang Liu and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Clinical Pharmacokinetics and Cancer Chemotherapy and Pharmacology.

In The Last Decade

Azra Hussaini

14 papers receiving 255 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Azra Hussaini United States 10 64 63 44 41 38 14 258
Renato Demarchi Foresto Brazil 8 36 0.6× 61 1.0× 37 0.8× 24 0.6× 33 0.9× 35 262
René Vos Netherlands 11 37 0.6× 36 0.6× 39 0.9× 24 0.6× 53 1.4× 16 334
Alpa J. Dherai India 13 85 1.3× 40 0.6× 24 0.5× 35 0.9× 76 2.0× 31 328
Muna Albayaty United Kingdom 11 49 0.8× 54 0.9× 43 1.0× 74 1.8× 83 2.2× 27 301
Lisa M. Arfons United States 8 46 0.7× 65 1.0× 39 0.9× 24 0.6× 65 1.7× 16 296
Annie Fang United States 13 117 1.8× 155 2.5× 40 0.9× 36 0.9× 59 1.6× 29 394
Iván de Jesús Ascencio-Montiel Mexico 8 35 0.5× 85 1.3× 22 0.5× 18 0.4× 36 0.9× 27 257
Herman Veenhof Netherlands 12 32 0.5× 58 0.9× 22 0.5× 17 0.4× 68 1.8× 14 618
Hye In Woo South Korea 12 37 0.6× 66 1.0× 101 2.3× 13 0.3× 58 1.5× 24 346
Nadia Ben Fredj Tunisia 13 90 1.4× 65 1.0× 28 0.6× 18 0.4× 35 0.9× 60 479

Countries citing papers authored by Azra Hussaini

Since Specialization
Citations

This map shows the geographic impact of Azra Hussaini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Azra Hussaini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Azra Hussaini more than expected).

Fields of papers citing papers by Azra Hussaini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Azra Hussaini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Azra Hussaini. The network helps show where Azra Hussaini may publish in the future.

Co-authorship network of co-authors of Azra Hussaini

This figure shows the co-authorship network connecting the top 25 collaborators of Azra Hussaini. A scholar is included among the top collaborators of Azra Hussaini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Azra Hussaini. Azra Hussaini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Hussaini, Azra, et al.. (2019). A Double‐Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects. Clinical and Translational Science. 13(2). 337–344. 12 indexed citations
2.
Marshall, William L., Jacqueline B. McCrea, Sreeraj Macha, et al.. (2018). Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects. The Journal of Clinical Pharmacology. 58(7). 897–904. 50 indexed citations
3.
Hussaini, Azra, Anthony J. Olszanski, Cy A. Stein, Bill Bosch, & Paul R. Nemeth. (2017). Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate. Cancer Chemotherapy and Pharmacology. 80(3). 479–486. 4 indexed citations
4.
Goldwater, Ronald, Azra Hussaini, Bill Bosch, & Paul R. Nemeth. (2017). Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies. Clinical Pharmacokinetics. 56(7). 803–813. 25 indexed citations
5.
Young, Malcolm A., et al.. (2017). Effect of Albiglutide on Cholecystokinin‐Induced Gallbladder Emptying in Healthy Individuals: A Randomized Crossover Study. The Journal of Clinical Pharmacology. 57(10). 1322–1329. 17 indexed citations
6.
Khalilieh, Sauzanne, Ka Lai Yee, Fan Li, et al.. (2017). A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers. Clinical Drug Investigation. 37(10). 975–984. 9 indexed citations
7.
Anderson, Matt S., Sauzanne Khalilieh, Ka Lai Yee, et al.. (2016). A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir. Clinical Pharmacokinetics. 56(6). 661–669. 25 indexed citations
8.
Green, Justin A., Khadeeja Mohamed, Navin Goyal, et al.. (2016). Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy. 60(12). 7321–7332. 23 indexed citations
9.
Hussaini, Azra, et al.. (2015). Pharmacokinetic properties of low-dose SoluMatrix meloxicam in healthy adults. Clinical Rheumatology. 35(4). 1099–1104. 6 indexed citations
10.
Rix, Peter J., Andrew Vick, Geoffrey E. Barker, et al.. (2014). Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Nebulized Sodium Nitrite (AIR001) Following Repeat-Dose Inhalation in Healthy Subjects. Clinical Pharmacokinetics. 54(3). 261–272. 43 indexed citations
11.
Wire, Mary Beth, Fang Lei, Azra Hussaini, Joseph F. Kleha, & Dickens Theodore. (2014). Lack of Clinically Significant Pharmacokinetic Interaction between the Thrombopoietin Receptor Agonist Eltrombopag and Hepatitis C Virus Protease Inhibitors Boceprevir and Telaprevir. Antimicrobial Agents and Chemotherapy. 58(11). 6704–6709. 5 indexed citations
12.
Green, Justin A., Bela Patel, Azra Hussaini, et al.. (2014). Tafenoquine at therapeutic concentrations does not prolong fridericia‐corrected QT interval in healthy subjects. The Journal of Clinical Pharmacology. 54(9). 995–1005. 29 indexed citations
13.
14.
Yin, Ophelia, Véronique Bédoucha, Tracey McCulloch, et al.. (2012). Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers. Cancer Chemotherapy and Pharmacology. 71(1). 219–226. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Renato Demarchi Foresto Breakdown of academic impact, for papers by René Vos Breakdown of academic impact, for papers by Alpa J. Dherai Breakdown of academic impact, for papers by Muna Albayaty Breakdown of academic impact, for papers by Lisa M. Arfons Breakdown of academic impact, for papers by Annie Fang Breakdown of academic impact, for papers by Iván de Jesús Ascencio-Montiel Breakdown of academic impact, for papers by Herman Veenhof Breakdown of academic impact, for papers by Hye In Woo Breakdown of academic impact, for papers by Nadia Ben Fredj
Rankless by CCL
2026